CL2013000369A1 - Anticuerpo que se une especificamente a la proteina de activacion fibroblastica (fap); polinucleotido que lo codifica; vector; celula huesped; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar cancer. - Google Patents
Anticuerpo que se une especificamente a la proteina de activacion fibroblastica (fap); polinucleotido que lo codifica; vector; celula huesped; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar cancer.Info
- Publication number
- CL2013000369A1 CL2013000369A1 CL2013000369A CL2013000369A CL2013000369A1 CL 2013000369 A1 CL2013000369 A1 CL 2013000369A1 CL 2013000369 A CL2013000369 A CL 2013000369A CL 2013000369 A CL2013000369 A CL 2013000369A CL 2013000369 A1 CL2013000369 A1 CL 2013000369A1
- Authority
- CL
- Chile
- Prior art keywords
- fap
- polynucleotide
- encodes
- antibody
- vector
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000004913 activation Effects 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000003328 fibroblastic effect Effects 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000040430 polynucleotide Human genes 0.000 title 1
- 108091033319 polynucleotide Proteins 0.000 title 1
- 239000002157 polynucleotide Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10172842 | 2010-08-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013000369A1 true CL2013000369A1 (es) | 2014-08-08 |
Family
ID=44629814
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013000369A CL2013000369A1 (es) | 2010-08-13 | 2013-02-06 | Anticuerpo que se une especificamente a la proteina de activacion fibroblastica (fap); polinucleotido que lo codifica; vector; celula huesped; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar cancer. |
| CL2016002116A CL2016002116A1 (es) | 2010-08-13 | 2016-08-22 | Anticuerpos anti-fap y métodos de utilización (divisional sol. n°369-13). |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016002116A CL2016002116A1 (es) | 2010-08-13 | 2016-08-22 | Anticuerpos anti-fap y métodos de utilización (divisional sol. n°369-13). |
Country Status (36)
| Country | Link |
|---|---|
| US (5) | US9011847B2 (es) |
| EP (2) | EP2603530B1 (es) |
| JP (4) | JP5793568B2 (es) |
| KR (2) | KR101780131B1 (es) |
| CN (2) | CN103154038B (es) |
| AR (2) | AR082629A1 (es) |
| AU (1) | AU2011288487B2 (es) |
| BR (1) | BR112013003361B8 (es) |
| CA (1) | CA2806021C (es) |
| CL (2) | CL2013000369A1 (es) |
| CO (1) | CO6670523A2 (es) |
| CR (2) | CR20180142A (es) |
| DK (1) | DK2603530T3 (es) |
| EA (2) | EA037977B1 (es) |
| EC (1) | ECSP13012440A (es) |
| ES (1) | ES2655616T3 (es) |
| HR (1) | HRP20172004T1 (es) |
| HU (1) | HUE036077T2 (es) |
| IL (2) | IL224355B (es) |
| LT (1) | LT2603530T (es) |
| MA (1) | MA34519B1 (es) |
| MX (2) | MX386437B (es) |
| MY (2) | MY175341A (es) |
| NO (1) | NO2603530T3 (es) |
| NZ (2) | NZ605980A (es) |
| PE (2) | PE20131209A1 (es) |
| PH (2) | PH12013500159B1 (es) |
| PL (1) | PL2603530T3 (es) |
| PT (1) | PT2603530T (es) |
| RS (1) | RS56702B1 (es) |
| SG (1) | SG187746A1 (es) |
| SI (1) | SI2603530T1 (es) |
| TW (2) | TWI556827B (es) |
| UA (2) | UA113712C2 (es) |
| WO (1) | WO2012020006A2 (es) |
| ZA (2) | ZA201600552B (es) |
Families Citing this family (128)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012006326A2 (pt) | 2009-09-29 | 2016-11-16 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, sequência de ácidos nucleicos, vetor de expressão, célula hospedeira procariótica ou eucariótica e invenção |
| WO2012020006A2 (en) * | 2010-08-13 | 2012-02-16 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
| PH12013501657A1 (en) | 2011-02-10 | 2013-10-07 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| EP3892640A1 (en) | 2011-08-23 | 2021-10-13 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
| EP2747781B1 (en) | 2011-08-23 | 2017-11-15 | Roche Glycart AG | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
| HRP20181355T1 (hr) | 2011-08-23 | 2018-10-19 | Roche Glycart Ag | Bispecifične molekule koje se vežu na antigen |
| BR112014030414A2 (pt) * | 2012-08-07 | 2018-05-29 | Roche Glycart Ag | combinação de um imunoconjugado, composição farmacêutica, uso de um imunoconjugado, métodos de tratamento e de estímulo, kit e invenção. |
| SG11201408526SA (en) | 2012-08-08 | 2015-03-30 | Roche Glycart Ag | Interleukin-10 fusion proteins and uses thereof |
| US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
| MX2015003616A (es) | 2012-10-08 | 2015-06-05 | Roche Glycart Ag | Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de uso. |
| CN105143270B (zh) | 2013-02-26 | 2019-11-12 | 罗切格利卡特公司 | 双特异性t细胞活化抗原结合分子 |
| US20140242080A1 (en) | 2013-02-26 | 2014-08-28 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| CN111423513A (zh) | 2014-02-06 | 2020-07-17 | 豪夫迈·罗氏有限公司 | 白介素-2融合蛋白和其用途 |
| GB201402006D0 (en) * | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
| WO2015117930A1 (en) * | 2014-02-06 | 2015-08-13 | F. Hoffmann-La Roche Ag | Interleukine 10 immunoconjugates |
| WO2015164723A1 (en) | 2014-04-25 | 2015-10-29 | The Trustees Of The University Of Pennsylvania | Methods and compositions for treating metastatic breast cancer and other cancers in the brain |
| MA44179B1 (fr) | 2014-05-13 | 2020-10-28 | Univ Pennsylvania | Compositions comprenant un virus adeno-associe exprimant des constructions a double anticorps et leurs utilisations |
| MX2017004526A (es) * | 2014-10-08 | 2017-06-07 | Hoffmann La Roche | Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos. |
| PE20170896A1 (es) | 2014-11-14 | 2017-07-12 | Hoffmann La Roche | Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf |
| DK4141032T3 (da) | 2014-11-20 | 2024-08-05 | Hoffmann La Roche | Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler og PD-1-aksebindende antagonister |
| EP3242683A1 (en) * | 2015-01-09 | 2017-11-15 | Mabimmune Diagnostics AG | Novel anti-fibroblast activation protein (fap) antibodies and uses derived thereof |
| GB201500875D0 (en) * | 2015-01-19 | 2015-03-04 | Philogen Spa | Antibodies for treatment and diagnosis |
| WO2016156291A1 (en) | 2015-03-31 | 2016-10-06 | F. Hoffmann-La Roche Ag | Antigen binding molecules comprising a trimeric tnf family ligand |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| LT3356411T (lt) | 2015-10-02 | 2021-09-10 | F. Hoffmann-La Roche Ag | Bispecifiniai antikūnai, specifiniai pd1 ir tim3 |
| PE20240096A1 (es) | 2015-10-02 | 2024-01-18 | Hoffmann La Roche | Anticuerpos biespecificos especificos para un receptor de tnf coestimulador |
| CN106928368B (zh) * | 2015-12-30 | 2020-10-13 | 广西医科大学 | 一种FAP纳米抗体Nb57 |
| EP3231813A1 (en) | 2016-03-29 | 2017-10-18 | F. Hoffmann-La Roche AG | Trimeric costimulatory tnf family ligand-containing antigen binding molecules |
| EP3455254B1 (en) | 2016-05-11 | 2021-07-07 | F. Hoffmann-La Roche AG | Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety |
| EP3243836A1 (en) | 2016-05-11 | 2017-11-15 | F. Hoffmann-La Roche AG | C-terminally fused tnf family ligand trimer-containing antigen binding molecules |
| EP3243832A1 (en) | 2016-05-13 | 2017-11-15 | F. Hoffmann-La Roche AG | Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety |
| CN106018780B (zh) * | 2016-05-17 | 2017-12-26 | 扬州大学 | 一种基于f1蛋白的检测4型禽腺病毒抗体的间接免疫荧光试剂盒 |
| CN109311851B (zh) | 2016-06-12 | 2021-08-10 | 豪夫迈·罗氏有限公司 | 二氢嘧啶基苯并氮杂䓬甲酰胺化合物 |
| BR112019000015A2 (pt) | 2016-06-30 | 2019-04-24 | Oncorus, Inc. | distribuição por vírus oncolítico pseudotipado de polipeptídeos terapêuticos |
| JP2018035137A (ja) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ | 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用 |
| TW201829463A (zh) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
| JP7125400B2 (ja) | 2016-12-19 | 2022-08-24 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 標的化４－１ｂｂ（ｃｄ１３７）アゴニストとの併用療法 |
| ES2847973T3 (es) | 2016-12-20 | 2021-08-04 | Hoffmann La Roche | Politerapia de anticuerpos biespecíficos anti-CD20/anti-CD3 y agonistas de 4-1BB (CD137) |
| EP3565843A1 (en) | 2017-01-03 | 2019-11-13 | H. Hoffnabb-La Roche Ag | Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9 |
| EP3565560B1 (en) | 2017-01-09 | 2024-05-29 | OnkosXcel Therapeutics, LLC | Predictive and diagnostic methods for prostate cancer |
| WO2018178055A1 (en) | 2017-03-29 | 2018-10-04 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
| WO2018178074A1 (en) | 2017-03-29 | 2018-10-04 | F. Hoffmann-La Roche Ag | Trimeric antigen binding molecules specific for a costimulatory tnf receptor |
| JP7205995B2 (ja) | 2017-03-29 | 2023-01-17 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 共刺激性ｔｎｆ受容体に対する二重特異性抗原結合分子 |
| HRP20221254T1 (hr) | 2017-04-03 | 2022-12-23 | F. Hoffmann - La Roche Ag | Imunokonjugati protutijela anti-pd-1 s mutacijskim polipeptidom interleukina-2 ili interleukina-15 |
| US20180340030A1 (en) * | 2017-04-04 | 2018-11-29 | Hoffmann-La Roche Inc. | Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap |
| SI3606955T1 (sl) | 2017-04-05 | 2025-03-31 | F. Hoffmann-La Roche Ag | Bispecifična protitelesa, ki specifično vežejo PD1 in LAG3 |
| BR112019021411A2 (pt) | 2017-04-13 | 2020-05-05 | Hoffmann La Roche | métodos para tratar ou retardar a progressão do câncer e para melhorar a função, usos de um imunoconjugado, de um agonista, de um antagonista, composições, kit e invenção |
| EP3688023B1 (en) | 2017-09-25 | 2025-08-27 | Shihuida Pharmaceutical Group (Jilin) Co., Ltd. | Methods and compositions for cancer treatment |
| US11786551B2 (en) | 2017-09-26 | 2023-10-17 | The Trustees Of The University Of Pennsylvania | Methods for treating heart disease via redirected T cell immunotherapies |
| JP2021500902A (ja) | 2017-11-01 | 2021-01-14 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 新規ｔｎｆファミリーリガンド三量体含有抗原結合分子 |
| US12227594B2 (en) * | 2017-11-01 | 2025-02-18 | Hoffmann-La Roche Inc. | Bispecific 2+1 contorsbodies |
| TW201930353A (zh) | 2017-11-01 | 2019-08-01 | 瑞士商赫孚孟拉羅股份公司 | 使用經靶向之ox40促效劑的組合療法 |
| CN109796532B (zh) * | 2017-11-17 | 2024-09-10 | 恺兴生命科技(上海)有限公司 | 靶向成纤维激活蛋白α的结合单元及其应用 |
| EP3502140A1 (en) | 2017-12-21 | 2019-06-26 | F. Hoffmann-La Roche AG | Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules |
| EP3731850A4 (en) | 2017-12-29 | 2021-12-01 | Oncorus, Inc. | ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES |
| KR102877915B1 (ko) * | 2018-02-05 | 2025-10-29 | 오리오니스 바이오사이언시즈 인코포레이티드 | 섬유아세포 결합제 및 이의 용도 |
| TWI841551B (zh) | 2018-03-13 | 2024-05-11 | 瑞士商赫孚孟拉羅股份公司 | 使用靶向4-1bb (cd137)之促效劑的組合療法 |
| CA3092002A1 (en) | 2018-03-13 | 2019-09-19 | F. Hoffmann-La Roche Ag | Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies |
| CN112469477A (zh) | 2018-04-04 | 2021-03-09 | Xencor股份有限公司 | 与成纤维细胞活化蛋白结合的异源二聚体抗体 |
| WO2019197600A1 (en) | 2018-04-13 | 2019-10-17 | F. Hoffmann-La Roche Ag | Her2-targeting antigen binding molecules comprising 4-1bbl |
| AR114789A1 (es) | 2018-04-18 | 2020-10-14 | Hoffmann La Roche | Anticuerpos anti-hla-g y uso de los mismos |
| JP7494129B2 (ja) * | 2018-05-16 | 2024-06-03 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６、及び線維芽細胞活性化タンパク質と結合するタンパク質 |
| EP3818082A1 (en) | 2018-07-04 | 2021-05-12 | F. Hoffmann-La Roche AG | Novel bispecific agonistic 4-1bb antigen binding molecules |
| WO2020070035A1 (en) | 2018-10-01 | 2020-04-09 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecules with trivalent binding to cd40 |
| CN112955468B (zh) * | 2018-10-01 | 2024-08-09 | 豪夫迈·罗氏有限公司 | 包含抗fap克隆212的双特异性抗原结合分子 |
| CR20210326A (es) | 2018-12-21 | 2021-09-10 | Hoffmann La Roche | Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor |
| US20200223925A1 (en) | 2018-12-21 | 2020-07-16 | Hoffmann-La Roche Inc. | Tumor-targeted superagonistic cd28 antigen binding molecules |
| WO2020208049A1 (en) | 2019-04-12 | 2020-10-15 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecules comprising lipocalin muteins |
| CN114127123A (zh) | 2019-06-26 | 2022-03-01 | 豪夫迈·罗氏有限公司 | 结合cea的抗体与4-1bbl的融合 |
| JP7354306B2 (ja) | 2019-06-27 | 2023-10-02 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 新規ｉｃｏｓ抗体及びそれらを含む腫瘍標的化抗原結合分子 |
| EP3763726A1 (en) | 2019-07-08 | 2021-01-13 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| HUE070009T2 (hu) | 2019-07-08 | 2025-05-28 | 3B Pharmaceuticals Gmbh | Fibroblaszt aktiváló protein ligandumot tartalmazó vegyületek és alkalmazásuk |
| EP3997104A1 (en) | 2019-07-08 | 2022-05-18 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| WO2021061708A1 (en) * | 2019-09-23 | 2021-04-01 | The Trustees Of The Univeristy Of Pennsylvania | Monoclonal antibody against canine fibroblast activation protein that cross-reacts with mouse and human fibroblast activation protein (fap) |
| JP7621344B2 (ja) | 2019-09-23 | 2025-01-24 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 線維芽細胞活性化タンパク質（ｆａｐ）を標的とすることによる腫瘍組織の破壊の方法 |
| JP2023509760A (ja) | 2020-01-08 | 2023-03-09 | シンシス セラピューティクス，インコーポレイテッド | Ａｌｋ５阻害剤複合体およびその使用 |
| CA3162009A1 (en) | 2020-01-09 | 2021-07-15 | F. Hoffmann-La Roche Ag | New 4-1bbl trimer-containing antigen binding molecules |
| AR121706A1 (es) | 2020-04-01 | 2022-06-29 | Hoffmann La Roche | Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap |
| KR20230010240A (ko) | 2020-05-11 | 2023-01-18 | 에프. 호프만-라 로슈 아게 | 변형된 pbmc 및 면역접합체를 이용한 병용 요법 |
| WO2021257808A2 (en) * | 2020-06-17 | 2021-12-23 | Proviva Therapeutics (Hong Kong) Limited | Antibodies to fibroblast activation protein and b7h3 |
| US12049515B2 (en) | 2020-06-23 | 2024-07-30 | Hoffmann-La Roche Inc. | Agonistic CD28 antigen binding molecules targeting Her2 |
| JP2023531067A (ja) | 2020-06-25 | 2023-07-20 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗ｃｄ３／抗ｃｄ２８二重特異性抗原結合分子 |
| CN112540176B (zh) * | 2020-07-08 | 2021-09-28 | 深圳霁因生物医药转化研究院 | 用于诊断fap表达异常相关疾病的试剂盒、方法及计算机可读存储介质 |
| AU2021311034A1 (en) | 2020-07-24 | 2023-02-23 | F. Hoffmann-La Roche Ag | Method for the expression of an antibody-multimer-fusion |
| EP4198050A4 (en) | 2020-08-11 | 2024-05-01 | Kanaph Therapeutics Inc. | FUSION PROTEIN WITH IL-12 AND ANTI-CD20 ANTIBODIES AND USE THEREOF |
| JP2023549316A (ja) * | 2020-11-16 | 2023-11-24 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｆａｐを標的としたｃｄ４０アゴニストとの併用療法 |
| EP4263609A1 (en) | 2020-12-17 | 2023-10-25 | F. Hoffmann-La Roche AG | Anti-hla-g antibodies and use thereof |
| EP4050018A1 (en) | 2021-01-07 | 2022-08-31 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| CN116940585A (zh) | 2021-01-07 | 2023-10-24 | 3B制药有限公司 | 包含成纤维细胞活化蛋白配体的化合物及其用途 |
| JP2024512709A (ja) | 2021-03-30 | 2024-03-19 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | プロテアーゼ活性化ポリペプチド |
| WO2023113806A1 (en) | 2021-12-16 | 2023-06-22 | Affinia Therapeutics, Inc. | Recombinant aav for treatment of neural disease |
| EP4323531A1 (en) | 2021-04-12 | 2024-02-21 | Affinia Therapeutics Inc. | Recombinant aav for treatment of neural disease |
| US20240199762A1 (en) * | 2021-04-23 | 2024-06-20 | Philogen S.P.A | Anti-fibroblast activation protein antibodies |
| AU2022264509A1 (en) | 2021-04-27 | 2023-12-14 | Generation Bio Co. | Non-viral dna vectors expressing therapeutic antibodies and uses thereof |
| AR126009A1 (es) | 2021-06-02 | 2023-08-30 | Hoffmann La Roche | Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam |
| JP2024527367A (ja) * | 2021-07-09 | 2024-07-24 | イマジナブ・インコーポレーテッド | 診断及び療法剤のための新規抗体配列 |
| CA3228641A1 (en) * | 2021-08-24 | 2023-03-02 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Fap/cd40 binding molecule and medicinal use thereof |
| EP4148067A1 (en) | 2021-09-08 | 2023-03-15 | F. Hoffmann-La Roche AG | Method for the expression of an antibody-multimer-fusion |
| WO2023073225A1 (en) | 2021-11-01 | 2023-05-04 | F. Hoffmann-La Roche Ag | Treatment of cancer using a hla-a2/wt1 x cd3 bispecific antibody and a 4-1bb (cd137) agonist |
| TW202339797A (zh) | 2021-12-14 | 2023-10-16 | 瑞士商赫孚孟拉羅股份公司 | 使用ｈｌａ－ａ２ｍａｇｅ－ａ４ｘｃｄ３雙特異性抗體及４－１ｂｂ（ｃｄ１３７）促效劑治療癌症 |
| CR20240246A (es) | 2021-12-20 | 2024-07-19 | Hoffmann La Roche | Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden |
| KR20230121685A (ko) | 2022-02-11 | 2023-08-21 | 주식회사 카나프테라퓨틱스 | Il-12 및 항-fap 항체를 포함하는 융합단백질 및 항암제를 포함하는 암 치료용 약학 조성물 |
| CA3245737A1 (en) | 2022-03-14 | 2023-09-21 | Generation Bio Co. | PRIME-BOOST HETEROLOGICAL VACCINE COMPOSITIONS AND METHODS OF USE |
| EP4499229A1 (en) | 2022-03-28 | 2025-02-05 | F. Hoffmann-La Roche AG | Interferon gamma variants and antigen binding molecules comprising these |
| CN114685673A (zh) * | 2022-03-29 | 2022-07-01 | 深圳医爱健康管理有限公司 | 成纤维细胞激活蛋白抗体及使用方法 |
| KR20230162310A (ko) | 2022-05-20 | 2023-11-28 | 주식회사 카나프테라퓨틱스 | Light 단백질 및 항-fap 항체를 포함하는 융합단백질 및 이의 용도 |
| EP4578877A1 (en) | 2022-08-03 | 2025-07-02 | Nanjing Leads Biolabs Co., Ltd. | Antibody fusion protein targeting fap and tgf-beta, and use thereof |
| EP4598566A1 (en) | 2022-10-07 | 2025-08-13 | Genethon | Immunotherapy of skeletal myopathies using anti-fap car-t cells |
| CN120344558A (zh) * | 2022-12-08 | 2025-07-18 | 上海星赛生物科技有限公司 | 双特异性/多特异性抗体及其用途 |
| CN120826234A (zh) | 2023-03-06 | 2025-10-21 | 豪夫迈·罗氏有限公司 | 抗EGFRvIII/抗CD3抗体与肿瘤靶向性4-1BB激动剂的组合疗法 |
| WO2024188966A1 (en) | 2023-03-13 | 2024-09-19 | F. Hoffmann-La Roche Ag | Treatment of cancer using an anti-hla-g/anti-cd3 bispecific antibody and a 4‑1bb (cd137) agonist |
| EP4688840A1 (en) | 2023-04-03 | 2026-02-11 | F. Hoffmann-La Roche AG | Agonistic split antibodies |
| CN120882744A (zh) | 2023-04-03 | 2025-10-31 | 豪夫迈·罗氏有限公司 | 一体化激动性抗体 |
| WO2024246086A1 (en) | 2023-06-01 | 2024-12-05 | F. Hoffmann-La Roche Ag | Immunostimulatory antigen binding molecules that specifically bind to bcma |
| CN121241068A (zh) | 2023-06-01 | 2025-12-30 | 豪夫迈·罗氏有限公司 | 靶向bcma和cd28的双特异性抗体 |
| CN121358775A (zh) | 2023-06-21 | 2026-01-16 | 豪夫迈·罗氏有限公司 | 利用靶向FAP的淋巴毒素β受体激动剂的组合疗法 |
| CN121443322A (zh) | 2023-07-03 | 2026-01-30 | 施慧达药业集团(吉林)有限公司 | 蛋白质异二聚体的治疗用途 |
| US20250186630A1 (en) | 2023-12-12 | 2025-06-12 | Viewpoint Molecular Targeting, Inc. | Fibroblast activation protein targeting peptides |
| WO2025129201A1 (en) | 2023-12-15 | 2025-06-19 | Capstan Therapeutics, Inc. | Humanized anti-cd8 antibodies and uses thereof |
| WO2025152756A1 (zh) * | 2024-01-15 | 2025-07-24 | 迈威(上海)生物科技股份有限公司 | 重组抗fap抗体及其应用 |
| WO2025172587A1 (en) | 2024-02-16 | 2025-08-21 | Mestag Therapeutics Ltd | Binding constructs |
| WO2025172588A1 (en) | 2024-02-16 | 2025-08-21 | Mestag Therapeutics Ltd | Bispecific constructs directed against fap and ltbr |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025228289A1 (zh) * | 2024-04-28 | 2025-11-06 | 应世生物科技(南京)有限公司 | 一种靶向fap的抗体或其抗原结合片段及其应用 |
| CN118496382B (zh) * | 2024-05-22 | 2025-01-07 | 山东第一医科大学附属省立医院(山东省立医院) | 一种靶向fap的嵌合抗原受体、car-t细胞及其在肝纤维化中的应用 |
| CN118812715A (zh) * | 2024-07-02 | 2024-10-22 | 国睿(广州)生物科技有限公司 | 一种靶向成纤维活化蛋白α的纳米抗体及其应用 |
Family Cites Families (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| WO1993005804A1 (en) | 1991-09-18 | 1993-04-01 | Sloan-Kettering Institute For Cancer Research | Activated stromal fibroblast-specific antibody, f19 and methods of using the same |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE69334351D1 (de) | 1992-02-06 | 2011-05-12 | Novartis Vaccines & Diagnostic | Biosynthetisches Bindeprotein für Tumormarker |
| ATE196606T1 (de) | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| DE69830315T2 (de) | 1997-06-24 | 2006-02-02 | Genentech Inc., San Francisco | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| CA2312208C (en) | 1997-12-05 | 2011-01-25 | The Scripps Research Institute | Humanization of murine antibody |
| IL138608A0 (en) | 1998-04-02 | 2001-10-31 | Genentech Inc | Antibody variants and fragments thereof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| US6455677B1 (en) * | 1998-04-30 | 2002-09-24 | Boehringer Ingelheim International Gmbh | FAPα-specific antibody with improved producibility |
| EP0953639A1 (en) * | 1998-04-30 | 1999-11-03 | Boehringer Ingelheim International GmbH | FAPalpha-specific antibody with improved producibility |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
| PT1914244E (pt) | 1999-04-09 | 2013-07-26 | Kyowa Hakko Kirin Co Ltd | Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico |
| BR0014480A (pt) | 1999-10-04 | 2002-06-11 | Medicago Inc | Método para regular a transcrição de genes estranhos |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| JP4668498B2 (ja) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | ポリペプチドの製造方法 |
| IL149809A0 (en) | 1999-12-15 | 2002-11-10 | Genentech Inc | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| WO2001049698A1 (en) | 1999-12-29 | 2001-07-12 | Immunogen, Inc. | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
| EP1268550A2 (en) | 2000-03-17 | 2003-01-02 | Boehringer Ingelheim Pharma KG | Human fap-alpha-specific antibodies |
| CN100390288C (zh) | 2000-04-11 | 2008-05-28 | 杰南技术公司 | 多价抗体及其应用 |
| JP4936299B2 (ja) | 2000-08-21 | 2012-05-23 | メレクシス・テクノロジーズ・ナムローゼフェンノートシャップ | 磁場方向検出センサ |
| WO2002031140A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| AU2002239422B2 (en) | 2000-11-30 | 2006-12-07 | E. R. Squibb & Sons, L.L.C. | Transgenic transchromosomal rodents for making human antibodies |
| IL160170A0 (en) | 2001-08-03 | 2004-07-25 | Glycart Biotechnology Ag | A host cell engineered to produce a polypeptide having increased cytotoxicity |
| DK1443961T3 (da) | 2001-10-25 | 2009-08-24 | Genentech Inc | Glycoprotein-sammensætninger |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| CA2471551C (en) | 2001-12-27 | 2014-09-30 | Glycofi, Inc. | Methods to engineer mammalian-type carbohydrate structures |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| WO2003085119A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa |
| KR20050000380A (ko) | 2002-04-09 | 2005-01-03 | 교와 핫꼬 고교 가부시끼가이샤 | 게놈이 개변된 세포 |
| CA2481925A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for patients having human fc.gamma.riiia |
| AU2003236017B2 (en) | 2002-04-09 | 2009-03-26 | Kyowa Kirin Co., Ltd. | Drug containing antibody composition |
| AU2003236015A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | Process for producing antibody composition |
| US7749753B2 (en) | 2002-04-09 | 2010-07-06 | Kyowa Hakko Kirin Co., Ltd | Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost |
| CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
| WO2004024927A1 (en) | 2002-09-12 | 2004-03-25 | Greenovation Biotech Gmbh | Protein production method |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2004056312A2 (en) | 2002-12-16 | 2004-07-08 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| CA2549932C (en) | 2002-12-20 | 2013-08-20 | Greenovation Biotech Gmbh | Production of heterologous glycosylated proteins in bryophyte cells |
| ES2897506T3 (es) | 2003-01-09 | 2022-03-01 | Macrogenics Inc | Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos |
| US20050079574A1 (en) | 2003-01-16 | 2005-04-14 | Genentech, Inc. | Synthetic antibody phage libraries |
| PL222221B1 (pl) | 2003-01-22 | 2016-07-29 | Glycart Biotechnology Ag | Sposób wytwarzania polipeptydu w komórce gospodarza |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| JPWO2005035586A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | 融合蛋白質組成物 |
| US20070134759A1 (en) | 2003-10-09 | 2007-06-14 | Harue Nishiya | Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase |
| DK2380910T3 (en) | 2003-11-05 | 2015-10-19 | Roche Glycart Ag | Antigen binding molecules with increased Fc receptor binding affinity and effector function |
| DK2489364T3 (en) | 2003-11-06 | 2015-03-02 | Seattle Genetics Inc | Monomethylvaline compounds conjugated to antibodies |
| JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
| WO2005097832A2 (en) | 2004-03-31 | 2005-10-20 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| NZ549872A (en) | 2004-04-13 | 2009-09-25 | Hoffmann La Roche | Anti-P-selectin antibodies |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| HUE030079T2 (en) | 2004-09-23 | 2017-04-28 | Genentech Inc | Cysteine-manipulated antibodies and conjugates |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| US8679490B2 (en) | 2005-11-07 | 2014-03-25 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
| US20070237764A1 (en) | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| EP1806365A1 (en) * | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them |
| JP2009536527A (ja) | 2006-05-09 | 2009-10-15 | ジェネンテック・インコーポレーテッド | 最適化されたスキャフォールドを備えた結合ポリペプチド |
| ES2399075T3 (es) | 2006-08-30 | 2013-03-25 | Genentech, Inc. | Anticuerpos multiespecíficos |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| SG178443A1 (en) * | 2009-08-17 | 2012-04-27 | Roche Glycart Ag | Targeted immunoconjugates |
| BR112012006326A2 (pt) | 2009-09-29 | 2016-11-16 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, sequência de ácidos nucleicos, vetor de expressão, célula hospedeira procariótica ou eucariótica e invenção |
| CA2776037A1 (en) * | 2009-10-02 | 2011-04-07 | Ludwig Institute For Cancer Research Ltd | Anti-fibroblast activation protein antibodies and methods and uses thereof |
| WO2012020006A2 (en) | 2010-08-13 | 2012-02-16 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
| PH12013501657A1 (en) | 2011-02-10 | 2013-10-07 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| BR112014030414A2 (pt) | 2012-08-07 | 2018-05-29 | Roche Glycart Ag | combinação de um imunoconjugado, composição farmacêutica, uso de um imunoconjugado, métodos de tratamento e de estímulo, kit e invenção. |
| SG11201408526SA (en) | 2012-08-08 | 2015-03-30 | Roche Glycart Ag | Interleukin-10 fusion proteins and uses thereof |
| UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| RU2015152077A (ru) | 2013-05-07 | 2017-06-13 | Ф.Хоффманн-Ля Рош Аг | Тримерные антигенсвязывающие молекулы |
| MX2017004526A (es) | 2014-10-08 | 2017-06-07 | Hoffmann La Roche | Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos. |
-
2011
- 2011-08-09 WO PCT/EP2011/063648 patent/WO2012020006A2/en not_active Ceased
- 2011-08-09 EP EP11740932.6A patent/EP2603530B1/en active Active
- 2011-08-09 RS RS20180011A patent/RS56702B1/sr unknown
- 2011-08-09 UA UAA201605049A patent/UA113712C2/uk unknown
- 2011-08-09 KR KR1020157008218A patent/KR101780131B1/ko active Active
- 2011-08-09 PE PE2013000250A patent/PE20131209A1/es active IP Right Grant
- 2011-08-09 NZ NZ605980A patent/NZ605980A/en unknown
- 2011-08-09 EA EA201790309A patent/EA037977B1/ru not_active IP Right Cessation
- 2011-08-09 NZ NZ703653A patent/NZ703653A/en not_active IP Right Cessation
- 2011-08-09 HR HRP20172004TT patent/HRP20172004T1/hr unknown
- 2011-08-09 SI SI201131379T patent/SI2603530T1/en unknown
- 2011-08-09 CN CN201180049329.1A patent/CN103154038B/zh active Active
- 2011-08-09 PE PE2017001410A patent/PE20171512A1/es unknown
- 2011-08-09 HU HUE11740932A patent/HUE036077T2/hu unknown
- 2011-08-09 US US13/205,743 patent/US9011847B2/en active Active
- 2011-08-09 BR BR112013003361A patent/BR112013003361B8/pt active IP Right Grant
- 2011-08-09 DK DK11740932.6T patent/DK2603530T3/en active
- 2011-08-09 MX MX2017006572A patent/MX386437B/es unknown
- 2011-08-09 CR CR20180142A patent/CR20180142A/es unknown
- 2011-08-09 CA CA2806021A patent/CA2806021C/en active Active
- 2011-08-09 PT PT117409326T patent/PT2603530T/pt unknown
- 2011-08-09 MX MX2013001268A patent/MX358859B/es active IP Right Grant
- 2011-08-09 MA MA35725A patent/MA34519B1/fr unknown
- 2011-08-09 MY MYPI2013700230A patent/MY175341A/en unknown
- 2011-08-09 KR KR1020137006274A patent/KR101673653B1/ko active Active
- 2011-08-09 EP EP17198743.1A patent/EP3333194B1/en active Active
- 2011-08-09 JP JP2013523589A patent/JP5793568B2/ja active Active
- 2011-08-09 PH PH1/2013/500159A patent/PH12013500159B1/en unknown
- 2011-08-09 SG SG2013009238A patent/SG187746A1/en unknown
- 2011-08-09 LT LTEP11740932.6T patent/LT2603530T/lt unknown
- 2011-08-09 CN CN201610230190.5A patent/CN105884898B/zh active Active
- 2011-08-09 ES ES11740932.6T patent/ES2655616T3/es active Active
- 2011-08-09 AU AU2011288487A patent/AU2011288487B2/en active Active
- 2011-08-09 MY MYPI2016002343A patent/MY184879A/en unknown
- 2011-08-09 NO NO11740932A patent/NO2603530T3/no unknown
- 2011-08-09 PL PL11740932T patent/PL2603530T3/pl unknown
- 2011-08-09 EA EA201300239A patent/EA034742B1/ru not_active IP Right Cessation
- 2011-08-10 TW TW100128607A patent/TWI556827B/zh active
- 2011-08-10 TW TW105119038A patent/TWI599578B/zh active
- 2011-08-11 AR ARP110102921 patent/AR082629A1/es active IP Right Grant
- 2011-09-08 UA UAA201303027A patent/UA112416C2/uk unknown
-
2013
- 2013-01-17 CO CO13008399A patent/CO6670523A2/es active IP Right Grant
- 2013-01-21 IL IL224355A patent/IL224355B/en active IP Right Grant
- 2013-01-28 CR CR20130038A patent/CR20130038A/es unknown
- 2013-02-06 CL CL2013000369A patent/CL2013000369A1/es unknown
- 2013-02-13 EC ECSP13012440 patent/ECSP13012440A/es unknown
-
2015
- 2015-03-18 US US14/661,839 patent/US10253110B2/en active Active
- 2015-03-18 US US14/661,833 patent/US10577429B2/en active Active
- 2015-04-24 JP JP2015089640A patent/JP2015180632A/ja not_active Withdrawn
-
2016
- 2016-01-26 ZA ZA2016/00552A patent/ZA201600552B/en unknown
- 2016-01-26 ZA ZA2016/00551A patent/ZA201600551B/en unknown
- 2016-02-07 IL IL244000A patent/IL244000A0/en active IP Right Grant
- 2016-08-22 CL CL2016002116A patent/CL2016002116A1/es unknown
-
2017
- 2017-08-08 PH PH12017501417A patent/PH12017501417A1/en unknown
-
2018
- 2018-01-04 JP JP2018000112A patent/JP2018099120A/ja not_active Withdrawn
-
2019
- 2019-04-08 US US16/378,320 patent/US11332545B2/en active Active
- 2019-10-25 AR ARP190103090A patent/AR117658A2/es unknown
-
2020
- 2020-04-09 JP JP2020070164A patent/JP7017599B2/ja active Active
-
2022
- 2022-05-13 US US17/663,396 patent/US12286486B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013000369A1 (es) | Anticuerpo que se une especificamente a la proteina de activacion fibroblastica (fap); polinucleotido que lo codifica; vector; celula huesped; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar cancer. | |
| CL2013000566A1 (es) | Proteina de union a antigeno que une her3; acido nucleico que la codifica; vector de expresion; celula huesped recombinante; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar cancer. | |
| CL2011002482A1 (es) | Anticuerpo biespecificos que se une especificamente a las proteinas erbb-3 humana y c-met humana; acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar cancer | |
| CL2014002750A1 (es) | Anticuerpo aislado o fragmento que se enlaza a un estado inactiva de un receptor her; composición farmacéutica que lo comprende; uso del anticuerpo para tratar cancer | |
| CL2009000459A1 (es) | Anticuerpo se une a la proteina rgm a; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; construccion de anticuerpos que comprende dicha proteina; conjugado de anticuerpos que comprende a la construccion; uso. | |
| CL2013000930A1 (es) | Anticuerpo para interleuquina 17 (il-17); uso de dicho anticuerpo para tratar soriasis usando antagonistas de il-17. | |
| IL262073B (en) | Antibody drug conjugates (adc) that bind to 191p4d12 proteins | |
| CL2014000631A1 (es) | Molecula de union que se une a cd134 (ox40); molecula de acido nucleico que la codifica; vector; celula huesped; proceso de preparacion; composicion farmaceutica que la comprende; y su uso para tratar cancer. | |
| CL2011002304A1 (es) | Anticuerpo multiespecifico que comprende un dominio de union al antigeno que se une a egfr y a her3; acido nucleico que lo codifica; celula huesped; metodo de produccion; inmunoconjugado; formulacion farmaceutica que comprende el anticuerpo; y su uso para tratar el cancer. | |
| CL2015000094A1 (es) | Compuestos derivados de imidazotriazincarbonitrilos, inhibidores de la proteina cinasa; composicion farmaceutica que los comprende; y su uso para tratar el cancer, psoriasis y artritis reumatoide. | |
| CL2013001776A1 (es) | Anticuerpo aislado que se une a mesotelina; acido nucleico que la codifica; celula huesped; metodo de produccion; inmunoconjugado; formulacion farmaceutica que lo comprende; su uso para tratar cancer; y metodo de deteccion de mesotelina humana. | |
| CL2013003640A1 (es) | Proteina de union a il-17, construccion que comprende dicha proteina, un polipeptido ligador o un dominio constante de una inmunoglobulina; conjugado de dicha proteina; acido nucleico que la codifica; vector; celula huesped, metodo de produccion; composicion que la comprende; y su uso para reducir la actividad de la il-17 en una patologia en la cual il-17 es perjudicial (div.sol.2129-11). | |
| CL2014001888A1 (es) | Anticuerpo aislado que se une a la proteina 5 relacionada con el receptor de lipoproteina de baja densidad (lrp5); acido nucleico que lo codifica; celula huesped; metodo de produccion; formulaciom farmaceutica que lo comprende; y su uso para tratar retinopatías. | |
| CL2014000699A1 (es) | Proteina de union al antigeno cd27l; acido nucleico que la codifica; vector de expresion; celula huesped recombinante; composicion que la comprende; su uso para tratar cancer, trastornos autoinmunitarios o inflamatorios; y metodo para elaborar un conjugado anticuerpo cd27l-farmaco. | |
| CL2011002756A1 (es) | Anticuerpo que se enlaza a la proteina del complemento c3b humana o de cinomolgo; composicion farmaceutica, acido nucleico, vector y celula huesped que comprenden dicho anticuerpo; uso para tratar degeneracion macular relacionada con la edad. | |
| CL2013000074A1 (es) | Proteina de union con capacidad de unir un par de antigenos; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; conjugado que comprende dicha proteina de union; y sus usos. | |
| BR112013013781A2 (pt) | anticorpos humanizados para liv-1 e uso dos mesmos para tratar câncer | |
| CL2014000114A1 (es) | Anticuerpo que se une a r-espondina 1 humana (rspo1); polipéptido que comprende un anticuerpo; composición farmacéutica que comprende el anticuerpo; uso para inhibor el crecimiento de un tumor. | |
| BR112015007120A2 (pt) | anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo | |
| CL2011000086A1 (es) | Anticuerpo aislado o proteina funcional contra el polipeptido baffr que inhibe la proliferacion de celulas b; secuencia nucleotidicas de dicho anticuerpo; vector y celula huesped que comprende dicha secuencia; y su uso para tratar enfermedades autoinmunes o neoplasias de celulas b. | |
| CL2014003140A1 (es) | Anticuerpos aislado que se une a ly6e; metodo de produccion; inmunoconjugado que lo contiene; formulacion farmaceutica que lo contiene y métodos de uso. | |
| CL2013001107A1 (es) | Polipeptido derivado de la il-2 con actividad agonista; proteina de fusion que lo comprende; composicion farmaceutica que lo comprende; y su uso para tratar cancer y enfermedades infecciosas cronicas. | |
| CL2013003043A1 (es) | Anticuerpos de un único dominio variable dab que se unen a cd40 humano; ácido nucleico que codifica dicho anticuerpo; vector y célula huésped que lo comprenden; composición farmacéutica; uso de dichos anticuerpos para tratar enfermedad inmune. | |
| CL2013000545A1 (es) | Anticuerpo anti-ox40; acido nucleico que lo codifica; celula huesped; metodo de produccion; y su uso para tratar cancer o una enfermedad autoinmune. | |
| CL2013001279A1 (es) | Anticuerpo humano aislado o fragmento de union a antigeno del mismo que se une especificamente y neutraliza la actividad del ligando 1a de tipo tnf humano (htl1a); molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso. |